Emcure Pharmaceuticals Limited has successfully completed its compliance requirements for share dematerialization for the quarter ended March 31, 2026. Through its Registrar and Share Transfer Agent, MUFG Intime India Private Limited, the company has confirmed that all securities received from depository participants were duly verified, mutilated, and cancelled as per standard protocols. This ensures that the register of members remains accurate and updated within the prescribed regulatory timelines.
Share Dematerialization Processing
Emcure Pharmaceuticals Limited has announced the successful conclusion of its share dematerialization processes for the final quarter of the financial year, covering the period from January 1, 2026, to March 31, 2026. The process involves converting physical share certificates into electronic form, a critical step in maintaining efficient capital market operations.
Compliance and Verification
The company, in coordination with its Registrar and Share Transfer Agent, MUFG Intime India Private Limited, confirmed that all securities presented for dematerialization during the quarter were processed in accordance with established requirements. This process includes the mutilation and cancellation of physical certificates following verification, ensuring that the depositories reflect the accurate electronic records of share ownership.
Updated Records
Following the successful verification and cancellation of the certificates, the company has updated its register of members to reflect the appropriate changes in registered ownership. These measures ensure that Emcure Pharmaceuticals continues to maintain robust governance standards and transparency for its shareholders and market participants.
Source: BSE
